Increase efficiencies and productivity by automating core reporting tasks for medical writing.
Automate core regulatory report documents across the CTD pyramid and dramatically accelerate submission timelines.
Why neuro-symbolic AI is becoming essential for trusted regulatory workflows
By Emmanuel Walckenaer, CEO of Yseop
Artificial intelligence has made remarkable progress in recent years. Systems that once struggled to produce coherent text can now summarize clinical results, synthesize scientific literature, and draft complex documents in seconds. For teams working across vast volumes of regulatory and clinical documentation, this represents a genuine breakthrough.
But in life sciences, the real challenge is not what AI can generate. It is whether that output can be trusted.
Regulatory documents sit at the center of how therapies reach patients. Every submission must meet strict standards of accuracy, consistency, and traceability. Health authorities expect every claim to be verifiable, every number traceable to its source, and every process fully auditable. These are not preferences—they are the foundation of regulated industries.
In this environment, speed alone is not enough.
Over the past two years, the pharmaceutical industry has moved rapidly from experimentation to early adoption of generative AI. Teams are using these technologies to accelerate medical writing, summarize clinical data, and support document preparation. In many cases, the gains are real.
But as organizations move beyond pilots and attempt to integrate AI into real regulatory workflows, a consistent pattern is emerging across the industry.
Many organizations are encountering the same challenge. Early results are promising, but scaling proves far more difficult than expected. What works in isolated use cases begins to break down when applied across full regulatory processes. Variability appears. Outputs become harder to control. Traceability becomes more difficult to guarantee.
This is not a limitation of a single tool. It reflects a broader shift across the field of AI itself. As these systems move into high-stakes environments, it is becoming clear that generation alone is not enough.
Generating content is easy. Ensuring that content is accurate, repeatable, and traceable at scale is where the real challenge begins.
This is where many initiatives stall.
For AI to truly transform regulatory operations, it must meet a higher standard. At Yseop, we define that standard as Regulatory-Grade AI.
In regulated industries, reliability is not optional.
Any system contributing to regulatory submissions must satisfy three essential requirements: it must be accurate, ensuring outputs faithfully reflect the underlying scientific evidence; repeatable, producing consistent results under the same conditions; and traceable, allowing organizations to understand how outputs were generated and how conclusions were derived.
These principles mirror the same expectations that already govern regulated processes across the pharmaceutical industry. Regulatory authorities do not approve technologies; they approve processes that guarantee reliability, accountability, and data integrity.
As AI becomes embedded in regulatory workflows, it must meet those same expectations. This is why we believe the next phase of AI adoption in life sciences will be defined by Regulatory-Grade AI.
Achieving this level of reliability requires a shift in how AI systems are designed—moving beyond purely generative models toward hybrid, neuro-symbolic architectures that combine generation with reasoning and control.
These systems are designed from the ground up for regulated environments.
Generative AI represents an extraordinary technological breakthrough. Large language models can synthesize information, summarize research, and produce natural language with remarkable fluency. For regulatory teams, this opens powerful possibilities — drafting summaries, assembling document sections, and transforming structured data into narrative text can now happen dramatically faster.
But generative AI systems were not designed with regulated environments in mind.
They are probabilistic by nature, producing outputs based on statistical predictions rather than deterministic reasoning. As a result, the same input can produce different outputs. In many contexts, this flexibility is acceptable — even beneficial. In regulatory documentation, it introduces risk.
Researchers have also documented the phenomenon of hallucinations, where models generate plausible but incorrect information. While relatively rare, even small inaccuracies can create significant challenges in processes where precision and accountability are essential.
As organizations move beyond pilots and attempt to integrate AI into real regulatory workflows, a consistent pattern is emerging. What works in isolated use cases begins to break down when applied across full regulatory processes. Variability appears. Outputs become harder to control. Traceability becomes more difficult to guarantee.
Generative AI is therefore an important part of the solution. But on its own, it cannot guarantee the reliability required for regulatory work. Moving from faster drafting to trusted execution requires more than a language model — it requires systems designed to control, validate, and explain what is generated.
Achieving regulatory-grade reliability requires a different architectural approach. This is where neuro-symbolic AI becomes critical—and increasingly unavoidable.
Neuro-symbolic AI combines two historically separate paradigms: neural networks and symbolic AI. It combines models that generate and interpret complex language with systems that apply rules, enforce constraints, and ensure consistency.
This shift is not theoretical. It reflects a broader evolution across the AI field.
At AWS re:Invent it was described it as:
“An inflection point… the convergence of the old school and the new school.”
As AI moves into high-stakes applications, that convergence becomes essential. Systems must not only generate content, but also reason, validate, and explain.
“The next wave of progress will involve a sweeping embrace of neurosymbolic AI… essential for high-stakes decision-making.”
Even at the architectural level, this direction is becoming clearer.
"Right now, the polytheistic approach seems to be winning out"
In other words, no single model is sufficient.
This evolution is already visible in advanced research. DeepMind’s AlphaGeometry offers a clear example: a neural model proposes solutions, while a symbolic system verifies them with mathematical certainty—reaching the level of an International Mathematical Olympiad gold medalist.
The principle is simple.
Neural systems generate possibilities. Symbolic systems verify truth.
In pharmaceutical regulatory workflows, this distinction is critical. Every output must be defensible. Every decision must be auditable. Every process must be reproducible. Systems that cannot guarantee consistency or explain their reasoning introduce risks that organizations cannot accept.
Neuro-symbolic architectures address this directly—combining generative flexibility with deterministic control, and enabling AI to operate within the reliability standards required for regulated environments.
The first wave of AI adoption focused on accelerating document drafting. The next phase will focus on something more ambitious: enabling AI systems to participate in and coordinate complex regulatory workflows.
Regulatory processes involve far more than writing text. They require coordinating data across documents, applying regulatory rules, validating outputs, and ensuring consistency across entire submission packages.
Increasingly, these tasks will be supported by AI agents capable of executing and coordinating work across large volumes of documentation.
In regulated environments, however, these agents cannot operate without structure and oversight. They must function within systems that enforce rules, validate outputs, and maintain full traceability.
In this model, trust is not an afterthought. It is a design principle.
AI systems execute and coordinate tasks. Human experts remain responsible for oversight, interpretation, and final decisions.
The pharmaceutical industry is entering a new phase of AI adoption. The first wave demonstrated that generative AI can accelerate content creation. The next phase will be defined by something more fundamental: operational trust.
As organizations begin deploying AI systems— and increasingly AI agents—into core regulatory workflows, the key question will not be how fast these systems are.
It will be whether they can be relied upon.
At Yseop, we have been addressing this challenge for years—building systems designed specifically for regulated environments where reliability is non-negotiable.
Long before generative AI became mainstream, we developed systems combining symbolic reasoning, structured regulatory knowledge, and automation at scale. Today, this foundation allows us to integrate generative AI within architectures designed for control and reliability.
The result is not simply faster document drafting—it is AI that can be trusted to operate within regulatory workflows.
The future of AI in life sciences will not be defined by how much content it can generate, but by how reliably it can operate.
That future belongs to regulatory-grade AI.